CYP19A1 and osteoporosis: Hence, in patients with lower intrinsic oestrogen levels—resulting in higher risk of osteoporosis—the breast recurrence risk is reduced in a similar way as in patients with intrinsic higher oestrogen levels treated with aromatase inhibitors.